Tuberculosis Research and Treatment最新文献_第8页

Comparison of DNA Extraction Protocols and Molecular Targets to Diagnose Tuberculous Meningitis. 比较诊断结核性脑膜炎的 DNA 提取方案和分子靶标。

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-05-30 DOI: 10.1155/2017/5089046

Flavia Silva Palomo, Martha Gabriela Celle Rivero, Milene Gonçalves Quiles, Fernando Pereira Pinto, Antonia Maria de Oliveira Machado, Antonio Carlos Campos Pignatari

{"title":"Comparison of DNA Extraction Protocols and Molecular Targets to Diagnose Tuberculous Meningitis.","authors":"Flavia Silva Palomo, Martha Gabriela Celle Rivero, Milene Gonçalves Quiles, Fernando Pereira Pinto, Antonia Maria de Oliveira Machado, Antonio Carlos Campos Pignatari","doi":"10.1155/2017/5089046","DOIUrl":"10.1155/2017/5089046","url":null,"abstract":"Tuberculous meningitis (TBM) is a severe form of extrapulmonary tuberculosis. The aims of this study were to evaluate in-house molecular diagnostic protocols of DNA extraction directly from CSF samples and the targets amplified by qPCR as an accurate and fast diagnosis of TBM. One hundred CSF samples from 68 patients suspected of TBM were studied. Four DNA extraction techniques (phenol-chloroform-thiocyanate guanidine, silica thiocyanate guanidine, resin, and resin with ethanol) were compared and CSF samples were used to determine the best target (IS6110, MPB64, and hsp65 KDa) by qPCR. The extraction protocol using the phenol-chloroform-thiocyanate guanidine showed the best results in terms of quantification and sensitivity of PCR amplification, presenting up to 10 times more DNA than the second best protocol, the silica guanidine thiocyanate. The target that showed the best result for TBM diagnosis was the IS6110. This target showed 91% sensitivity and 97% specificity when we analyzed the results by sample and showed 100% sensitivity and 98% specificity when we analyzed the results by patient. The DNA extraction with phenol-chloroform-thiocyanate guanidine followed by IS6110 target amplification has been shown to be suitable for diagnosis of TBM in our clinical setting.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"5089046"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5468578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35110458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TB Risk Perceptions among Medical Residents at a Tertiary Care Center in India. 印度三级医疗中心住院医师对结核病风险的认知

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-11-22 DOI: 10.1155/2017/7514817

Geeta S Pardeshi, Dileep Kadam, Ajay Chandanwale, Andrea Deluca, Pranali Khobragade, Malan Parande, Nishi Suryavanshi, Aarti Kinikar, Anita Basavaraj, Sunita Girish, Sangita Shelke, Nikhil Gupte, Jason Farley, Robert Bollinger

{"title":"TB Risk Perceptions among Medical Residents at a Tertiary Care Center in India.","authors":"Geeta S Pardeshi, Dileep Kadam, Ajay Chandanwale, Andrea Deluca, Pranali Khobragade, Malan Parande, Nishi Suryavanshi, Aarti Kinikar, Anita Basavaraj, Sunita Girish, Sangita Shelke, Nikhil Gupte, Jason Farley, Robert Bollinger","doi":"10.1155/2017/7514817","DOIUrl":"10.1155/2017/7514817","url":null,"abstract":"Setting: Government tertiary health care center in India.Objective: To understand the perceptions of medical residents about their risk of developing TB in the workplace.Design: Cross-sectional study in which a semistructured questionnaire which included an open-ended question to assess their main concerns regarding TB in workplace was used to collect data.Results: Out of 305 resident doctors approached, 263 (94%) completed a structured questionnaire and 200 of these responded to an open-ended question. Daily exposure to TB was reported by 141 (64%) residents, 13 (5%) reported a prior history of TB, and 175 (69%) respondents were aware of TB infection control guidelines. A majority reported concerns about acquiring TB (78%) and drug-resistant TB (88%). The key themes identified were concerns about developing drug-resistant TB (n = 100; 50%); disease and its clinical consequences (n = 39; 20%); social and professional consequences (n = 37; 19%); exposure to TB patients (n = 32; 16%); poor infection control measures (n = 27; 14%); and high workload and its health consequences (n = 16; 8%).Conclusion: Though many resident doctors were aware of TB infection control guidelines, only few expressed concern about lack of TB infection control measures. Doctors need to be convinced of the importance of these measures which should be implemented urgently.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"7514817"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35758453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tuberculosis Treatment Adherence of Patients in Kosovo. 科索沃结核病患者的治疗依从性。

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-11-05 DOI: 10.1155/2017/4850324

Shaip Krasniqi, Arianit Jakupi, Armond Daci, Bahri Tigani, Nora Jupolli-Krasniqi, Mimoza Pira, Valbona Zhjeqi, Burim Neziri

{"title":"Tuberculosis Treatment Adherence of Patients in Kosovo.","authors":"Shaip Krasniqi, Arianit Jakupi, Armond Daci, Bahri Tigani, Nora Jupolli-Krasniqi, Mimoza Pira, Valbona Zhjeqi, Burim Neziri","doi":"10.1155/2017/4850324","DOIUrl":"https://doi.org/10.1155/2017/4850324","url":null,"abstract":"Setting: The poor patient adherence in tuberculosis (TB) treatment is considered to be one of the most serious challenges which reflect the decrease of treatment success and emerging of the Multidrug Resistance-TB (MDR-TB). To our knowledge, the data about patients' adherence to anti-TB treatment in our country are missing.Objective: This study was aimed to investigate the anti-TB treatment adherence rate and to identify factors related to eventual nonadherence among Kosovo TB patients.Design: This study was conducted during 12 months, and the survey was a descriptive study using the standardized questionnaires with total 324 patients.Results: The overall nonadherence for TB patient cohort was 14.5%, 95% CI (0.109-0.188). Age and place of residence are shown to have an effect on treatment adherence. Moreover, the knowledge of the treatment prognosis, daily dosage, side effects, and length of treatment also play a role. This was also reflected in knowledge regarding compliance with regular administration of TB drugs, satisfaction with the treatment, interruption of TB therapy, and the professional monitoring in the administration of TB drugs.Conclusion: The level of nonadherence TB treatment in Kosovar patients is not satisfying, and more health care worker's commitments need to be addressed for improvement.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"4850324"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4850324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35242669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 33

Factors Associated with Mortality among Patients on TB Treatment in the Southern Region of Zimbabwe, 2013. 2013年津巴布韦南部地区接受结核病治疗的患者死亡率相关因素

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-03-02 DOI: 10.1155/2017/6232071

Kudakwashe C Takarinda, Charles Sandy, Nyasha Masuka, Patrick Hazangwe, Regis C Choto, Tsitsi Mutasa-Apollo, Brilliant Nkomo, Edwin Sibanda, Owen Mugurungi, Anthony D Harries, Nicholas Siziba

{"title":"Factors Associated with Mortality among Patients on TB Treatment in the Southern Region of Zimbabwe, 2013.","authors":"Kudakwashe C Takarinda, Charles Sandy, Nyasha Masuka, Patrick Hazangwe, Regis C Choto, Tsitsi Mutasa-Apollo, Brilliant Nkomo, Edwin Sibanda, Owen Mugurungi, Anthony D Harries, Nicholas Siziba","doi":"10.1155/2017/6232071","DOIUrl":"10.1155/2017/6232071","url":null,"abstract":"Background. In 2013, the tuberculosis (TB) mortality rate was highest in southern Zimbabwe at 16%. We therefore sought to determine factors associated with mortality among registered TB patients in this region. Methodology. This was a retrospective record review of registered patients receiving anti-TB treatment in 2013. Results. Of 1,971 registered TB patients, 1,653 (84%) were new cases compared with 314 (16%) retreatment cases. There were 1,538 (78%) TB/human immunodeficiency virus (HIV) coinfected patients, of whom 1,399 (91%) were on antiretroviral therapy (ART) with median pre-ART CD4 count of 133 cells/uL (IQR, 46-282). Overall, 428 (22%) TB patients died. Factors associated with increased mortality included being ≥65 years old [adjusted relative risk (ARR) = 2.48 (95% CI 1.35-4.55)], a retreatment TB case [ARR = 1.34 (95% CI, 1.10-1.63)], and being HIV-positive [ARR = 1.87 (95% CI, 1.44-2.42)] whilst ART initiation was protective [ARR = 0.25 (95% CI, 0.22-0.29)]. Cumulative mortality rates were 10%, 14%, and 21% at one, two, and six months, respectively, after starting TB treatment. Conclusion. There was high mortality especially in the first two months of anti-TB treatment, with risk factors being recurrent TB and being HIV-infected, despite a high uptake of ART.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"6232071"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34864044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immigrant Arrival and Tuberculosis among Large Immigrant- and Refugee-Receiving Countries, 2005-2009. 2005-2009年大型移民和难民接收国的移民抵达与结核病。

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-03-23 DOI: 10.1155/2017/8567893

Zachary White, John Painter, Paul Douglas, Ibrahim Abubakar, Howard Njoo, Chris Archibald, Jessica Halverson, John Robson, Drew L Posey

{"title":"Immigrant Arrival and Tuberculosis among Large Immigrant- and Refugee-Receiving Countries, 2005-2009.","authors":"Zachary White, John Painter, Paul Douglas, Ibrahim Abubakar, Howard Njoo, Chris Archibald, Jessica Halverson, John Robson, Drew L Posey","doi":"10.1155/2017/8567893","DOIUrl":"https://doi.org/10.1155/2017/8567893","url":null,"abstract":"Objective. Tuberculosis control in foreign-born populations is a major public health concern for Australia, Canada, New Zealand, United Kingdom, and the United States, large immigrant- and refugee-receiving countries that comprise the Immigration and Refugee Health Working Group (IRHWG). Identifying and comparing immigration and distribution of foreign-born tuberculosis cases are important for developing targeted and collaborative interventions. Methods. Data stratified by year and country of birth from 2005 to 2009 were received from these five countries. Immigration totals, tuberculosis case totals, and multidrug-resistant tuberculosis (MDR TB) case totals from source countries were analyzed and compared to reveal similarities and differences for each member of the group. Results. Between 2005 and 2009, there were a combined 31,785,002 arrivals, 77,905 tuberculosis cases, and 888 MDR TB cases notified at the federal level in the IRHWG countries. India, China, Vietnam, and the Philippines accounted for 41.4% of the total foreign-born tuberculosis cases and 42.7% of the foreign-born MDR tuberculosis cases to IRHWG. Interpretation. Collaborative efforts across a small number of countries have the potential to yield sizeable gains in tuberculosis control for these large immigrant- and refugee-receiving countries.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"8567893"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/8567893","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34928177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report. 无结核感染的hiv感染者免疫激活和利福平吸收的初步研究:简短报告。

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-12-21 DOI: 10.1155/2017/2140974

Christopher Vinnard, Isabel Manley, Brittney Scott, Mariana Bernui, Joella Adams, Sheryl Varghese, Isaac Zentner, Michele A Kutzler

{"title":"A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report.","authors":"Christopher Vinnard, Isabel Manley, Brittney Scott, Mariana Bernui, Joella Adams, Sheryl Varghese, Isaac Zentner, Michele A Kutzler","doi":"10.1155/2017/2140974","DOIUrl":"https://doi.org/10.1155/2017/2140974","url":null,"abstract":"Background: Rifampin malabsorption is frequently observed in tuberculosis patients coinfected with human immunodeficiency virus (HIV) but cannot be predicted by patient factors such as CD4+ T cell count or HIV viral load.Methods: We sought to describe the relationship between HIV-associated immune activation, measures of gut absorptive capacity and permeability, and rifampin pharmacokinetic parameters in a pilot study of 6 HIV-infected, tuberculosis-uninfected patients who were naïve to antiretroviral therapy.Results: The median rifampin area under the concentration-versus-time curve during the 8-hour observation period was 42.8 mg·hr/L (range: 21.2 to 57.6), with a median peak concentration of 10.1 mg/L (range: 5.3 to 12.5). We observed delayed rifampin absorption, with a time to maximum concentration greater than 2 hours, in 2 of 6 participants. There was a trend towards increased plasma concentrations of sCD14, a marker of monocyte activation in response to bacterial translocation, among participants with delayed rifampin absorption compared to participants with rapid absorption (p = 0.06).Conclusions: Delayed rifampin absorption may be associated with elevated markers of bacterial translocation among HIV-infected individuals naïve to antiretroviral therapy. This trial is registered with NCT01845298.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"2140974"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2140974","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35820664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The Bidirectional Relationship between Tuberculosis and Diabetes. 结核病与糖尿病的双向关系

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-11-12 DOI: 10.1155/2017/1702578

Ernest Yorke, Yacoba Atiase, Josephine Akpalu, Osei Sarfo-Kantanka, Vincent Boima, Ida Dzifa Dey

引用次数: 66

Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013. 2013年门诊保险理赔数据中的结核病检测使用和医疗支出。

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-10-23 DOI: 10.1155/2017/3816432

Kwame Owusu-Edusei, Carla A Winston, Suzanne M Marks, Adam J Langer, Roque Miramontes

{"title":"Tuberculosis Test Usage and Medical Expenditures from Outpatient Insurance Claims Data, 2013.","authors":"Kwame Owusu-Edusei, Carla A Winston, Suzanne M Marks, Adam J Langer, Roque Miramontes","doi":"10.1155/2017/3816432","DOIUrl":"https://doi.org/10.1155/2017/3816432","url":null,"abstract":"Objective: To evaluate TB test usage and associated direct medical expenditures from 2013 private insurance claims data in the United States (US).Methods: We extracted outpatient claims for TB-specific and nonspecific tests from the 2013 MarketScan® commercial database. We estimated average expenditures (adjusted for claim and patient characteristics) using semilog regression analyses and compared them to the Centers for Medicare and Medicaid Services (CMS) national reimbursement limits.Results: Among the TB-specific tests, 1.4% of the enrollees had at least one claim, of which the tuberculin skin test was most common (86%) and least expensive ($9). The T-SPOT® was the most expensive among the TB-specific tests ($106). Among nonspecific TB tests, the chest radiograph was the most used test (78%), while chest computerized tomography was the most expensive ($251). Adjusted average expenditures for the majority of tests (≈74%) were above CMS limits. We estimated that total United States medical expenditures for the employer-based privately insured population for TB-specific tests were $53.0 million in 2013, of which enrollees paid 17% ($9 million).Conclusions: We found substantial differences in TB test usage and expenditures. Additionally, employer-based private insurers and enrollees paid more than CMS limits for most TB tests.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"3816432"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/3816432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35730997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation. 减少结核分枝杆菌接种密度用于MGIT吡嗪酰胺药敏试验以防止假耐药结果并提高准确性:一项多中心评估。

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-11-08 DOI: 10.1155/2017/3748163

Glenn P Morlock, Frances C Tyrrell, Dorothy Baynham, Vincent E Escuyer, Nicole Green, Youngmi Kim, Patricia A Longley-Olson, Nicole Parrish, Courtney Pennington, Desmond Tan, Brett Austin, James E Posey

{"title":"Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.","authors":"Glenn P Morlock, Frances C Tyrrell, Dorothy Baynham, Vincent E Escuyer, Nicole Green, Youngmi Kim, Patricia A Longley-Olson, Nicole Parrish, Courtney Pennington, Desmond Tan, Brett Austin, James E Posey","doi":"10.1155/2017/3748163","DOIUrl":"https://doi.org/10.1155/2017/3748163","url":null,"abstract":"The primary platform used for pyrazinamide (PZA) susceptibility testing of Mycobacterium tuberculosis is the MGIT culture system (Becton Dickinson). Since false-resistant results have been associated with the use of this system, we conducted a multicenter evaluation to determine the effect of using a reduced cell density inoculum on the rate of false resistance. Two reduced inoculum densities were compared with that prescribed by the manufacturer (designated as \"BD\" method). The reduced inoculum methods (designated as \"A\" and \"C\") were identical to the manufacturer's protocol in all aspects with the exception of the cell density of the inoculum. Twenty genetically and phenotypically characterized M. tuberculosis isolates were tested in duplicate by ten independent laboratories using the three inoculum methods. False-resistant results declined from 21.1% using the standard \"BD\" method to 5.7% using the intermediate (\"A\") inoculum and further declined to 2.8% using the most dilute (\"C\") inoculum method. The percentages of the resistant results that were false-resistant declined from 55.2% for the \"BD\" test to 28.8% and 16.0% for the \"A\" and \"C\" tests, respectively. These results represent compelling evidence that the occurrence of false-resistant MGIT PZA susceptibility test results can be mitigated through the use of reduced inoculum densities.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":"2017 ","pages":"3748163"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/3748163","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35664806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Nanotechnology-Based Approach in Tuberculosis Treatment. 基于纳米技术的结核病治疗方法

Tuberculosis Research and Treatment Pub Date : 2017-01-01 Epub Date: 2017-01-22 DOI: 10.1155/2017/4920209

Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das

{"title":"Nanotechnology-Based Approach in Tuberculosis Treatment.","authors":"Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das","doi":"10.1155/2017/4920209","DOIUrl":"10.1155/2017/4920209","url":null,"abstract":"Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.","PeriodicalId":30261,"journal":{"name":"Tuberculosis Research and Treatment","volume":" ","pages":"4920209"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49279771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0